Alimta Approved as Maintenance Therapy for Advanced Lung Cancer

To prevent disease progression

Related Encyclopedia • Acidophilus • Adenocarcinoma of the Lung and Brain Metastases • Antioxidants • Basal Cell Carcinoma More... Related Healthscout Videos Tumor Detecting App: Medicine's Next Big Thing? Powerful Combo Reducing Lymphedema Fighting Breast Cancer on Your Lunch Break "Ippy:" A Melanoma Milestone More... Related Animations • Breast Self-Exam Video • Colon Cancer More... Related Drug Information • Epogen • Iressa • Klor-Con • Klor-Con ER More... Related News Articles • Smoking May Up Cancer Risk in Barrett's Esophagus Patients • Prostate Size May Be Clue to Severity of Cancer • Many Gay Men Would Support 'Home HIV Test': Study • Young Adults Who Quit Smoking Feel Better Quickly More...

MONDAY, July 6 (HealthDay News) -- The drug Alimta (pemetrexed) has been approved by the U.S. Food and Drug Administration to prevent progression of certain types of advanced or metastatic (spreading) lung cancer, the agency said Monday.

The drug, which hinders the needed absorption by certain tumors of B-vitamin folate, is newly approved for people whose tumor has shrunk or whose cancer has stabilized after chemotherapy.

Text Continues Below

---

Alimta was first approved in 2004 to treat the asbestos-linked cancer mesothelioma and, later, as an initial therapy for advanced non-small cell lung cancer, the FDA said in a news release.

Possible side effects may include blood cell damage, fatigue, nausea, loss of appetite, extremity numbness, and rash, the FDA said.

The drug is produced by Indianpolis-based Eli Lilly & Co.

More information

The FDA has more about this drug's history.

-- Scott Roberts